Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Laekna, Inc. ( (HK:2105) ) is now available.
Laekna, Inc. has successfully completed a Phase I Single Ascending Dose (SAD) study of its obesity treatment drug, LAE102. The study showed encouraging safety and tolerability results, with no serious adverse events reported. The results lay a strong foundation for future studies, including a Phase I Multiple Ascending Dose (MAD) study in China and a collaborative Phase I clinical study with Eli Lilly in the U.S. This progress positions Laekna as a promising player in obesity treatment, potentially impacting its industry standing and offering new hope for overweight and obese patients needing quality weight control options.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on developing innovative treatments, particularly in the area of obesity, utilizing monoclonal antibodies. LAE102, their internally discovered drug, targets ActRIIA which is involved in muscle regeneration and lipid metabolism. The company is engaged in clinical collaborations and aims to offer novel treatment options for weight control.
YTD Price Performance: 33.40%
Average Trading Volume: 10,312,629
Technical Sentiment Consensus Rating: Sell
See more data about 2105 stock on TipRanks’ Stock Analysis page.